Pittsburgh-area surgeon says he's seeing more young people with colorectal cancer

Colorectal cancer incidence is rising among Americans under 50, with a Pittsburgh surgeon reporting weekly diagnoses in patients in their 20s, 30s and 40s; screening age was recently lowered from 50 to 45 but experts say that change may be insufficient. Approximately three-quarters of under-50 patients are diagnosed at an advanced stage, and clinicians link the trend to obesity and consumption of ultra-processed foods; the shift implies growing demand for earlier diagnostic screening and oncology services, with implications for providers, diagnostics and treatment-focused healthcare firms.

Analysis

Market structure: Rising colorectal cancer incidence in <50s shifts demand toward diagnostics, endoscopy consumables, ambulatory surgery centers and oncology follow‑ups. Expect incremental colonoscopy/stool‑test volume growth of ~5–10% over 12–36 months in affected cohorts, benefiting diagnostics (DGX, LH) and screening specialist EXAS while raising procedure revenue for hospital/ASC operators (HCA, AMED). Processed‑food and obesity‑linked sectors face reputational/regulatory risk that could pressure select packaged‑food names by mid‑2026.

Risk assessment: Near‑term (days–weeks) headline risk can spike patient awareness and referral rates; short‑term (months) capacity and lab turnaround are bottlenecks; long‑term (years) structural higher incidence expands addressable market for diagnostics and targeted CRC drugs. Tail risks: payer reimbursement changes, USPSTF guideline reversals, or supply constraints for scopes; a negative large epidemiology study linking tests to overdiagnosis could compress pricing and volumes.

Trade implications: Direct plays: diagnostics labs (DGX, LH) and EXAS capture most upside; device/consumables exposure concentrated in BSX and JNJ; hospitals/ASCs (HCA) gain procedural revenue. Options: express bullish view via 9–18 month call spreads on EXAS and covered calls on HCA to monetize near‑term volatility. Rotate +1–3% overweight into healthcare diagnostics/devices and underweight packaged foods (KHC, GIS) over next 3–12 months.

Contrarian angles: Market may underprice capacity limits — colonoscopy throughput and specialist shortages could push patients toward non‑invasive tests, favoring EXAS and labs over scope‑makers. Conversely, broader screening could reduce late‑stage CRC drug demand, an overlooked negative for oncology therapeutics exposed to CRC; watch for this secular mix shift before buying oncology mid‑caps aggressively.

Key Decisions for Investors

• Establish a 2% portfolio position long Exact Sciences (EXAS) via a 9–12 month call spread (buy 1x LEAP/9–12m call, sell higher strike call) to cap premium; thesis: non‑invasive screening adoption to accelerate within 6–18 months, target 20–40% upside if volumes rise 5–10%.
• Add 1.5% long positions in Quest Diagnostics (DGX) and LabCorp (LH) (0.75% each) to capture higher test throughput; trim if quarter‑over‑quarter test volume growth <2% for two consecutive quarters (review at 90 days).
• Overweight HCA Healthcare (HCA) by +1% (buy shares) and sell 3–6 month covered calls to collect premium; rationale: higher procedural caseloads over next 12–24 months, exit if same‑store outpatient procedures do not grow >3% YoY within two quarters.
• Reduce packaged‑food exposure by 1–2% (trim KHC or GIS positions) and redeploy proceeds into diagnostics/devices; trigger to re‑enter if federal guidance explicitly exonerates processed foods or if food sector stock drops >10% relative to S&P within 6 months.